ClinicalTrials.gg
CompletedNCT06411860Updated Oct 23, 2026

A Study to Assess the Effect of Olpasiran on QT/QTc Intervals in Healthy Participants

A Phase 1 interventional study of Placebo and Olpasiran in Basic Science, sponsored by Amgen. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Amgen · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Nov 2024, 1 year 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The primary objective of the study is:

  • To assess the effects of a single therapeutic and supratherapeutic dose of olpasiran on the placebo-corrected change from baseline in QT corrected for heart rate (ΔΔQT)/QTc interval in healthy participants.
02

Conditions studied

  • Basic Science

Keywords

  • QT/QTc Intervals
  • Healthy Participants
  • Olpasiran
  • AMG 890
03

In context

Lead sponsor

Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.

Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provide prior to starting study activities.
  • Healthy male or female participants, between 18 and 60 years of age (inclusive) at the time of Screening. Females must be of nonchildbearing potential.
  • between 18 and 30 kg/m\^2 (inclusive) at the time of Screening. Participants must have a body mass ≥ 50kg.

Exclusion criteria

Exclusion Criteria:

  • History or evidence, at Screening or Check-in, of disorder, condition, or disease not otherwise excluded that, in the opinion of the Investigator (or designee), would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion.
  • History or current signs or symptoms of cardiovascular disease, including but not limited to myocardial infarction, congenital heart disease, valvular heart disease coronary revascularization, or angina.
  • History or evidence of clinically significant arrhythmia at screening, including any clinically significant findings on the taken at Check-in.
  • Systolic blood pressure > 150 mmHg or \< 90 mmHg, or diastolic blood pressure > 90 mmHg or \< 50 mmHg, or HR ≤ 40 and > 100 bpm, at Screening or Check-in; one repeat blood pressure measurement will be allowed at Screening and Check-in.
  • History suggestive of esophageal (including esophageal spasm, esophagitis), gastric, or duodenal ulceration or bowel disease (including but not limited to peptic ulceration, gastrointestinal bleeding, ulcerative colitis, Crohn's disease, or irritable bowel syndrome), or a history of gastrointestinal surgery other than uncomplicated appendectomy and hernia repair.
  • Inability to swallow oral medication or history of malabsorption syndrome.
  • History of , intolerance, or allergy to any drug compound, food, or other substance, unless approved by the Investigator (or designee) and in consultation with the Sponsor.
  • History of major bleeding disorder (for example: hemophilia, von Willebrand disease, clotting factor deficiencies, etc).
  • Participant has received a dose of an drug within the past 90 days or have previously completed or withdrawn from this study or any other study investigating olpasiran or have previously received olpasiran.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
32 participants (actual)

Study arms

  • Placebo comparator
    Treatment A

    All participants will be randomized to 1 of 12 treatment sequences and receive a single dose of one of the following treatments, according to the randomization schedule: Treatment A: placebo Treatment B: dose level 1 olpasiran Treatment C: dose level 2 olpasiran Treatment D: moxifloxacin

    Other: Placebo

  • Experimental
    Treatment B

    All participants will be randomized to 1 of 12 treatment sequences and receive a single dose of one of the following treatments, according to the randomization schedule: Treatment A: placebo Treatment B: dose level 1 olpasiran Treatment C: dose level 2 olpasiran Treatment D: moxifloxacin

    Drug: Olpasiran

  • Experimental
    Treatment C

    All participants will be randomized to 1 of 12 treatment sequences and receive a single dose of one of the following treatments, according to the randomization schedule: Treatment A: placebo Treatment B: dose level 1 olpasiran Treatment C: dose level 2 olpasiran Treatment D: moxifloxacin

    Drug: Olpasiran

  • Active comparator
    Treatment D

    All participants will be randomized to 1 of 12 treatment sequences and receive a single dose of one of the following treatments, according to the randomization schedule: Treatment A: placebo Treatment B: dose level 1 olpasiran Treatment C: dose level 2 olpasiran Treatment D: moxifloxacin

    Drug: Moxifloxacin

Interventions

  • OtherPlacebo

    Participants will receive a subcutaneous (SC) injection of placebo.

  • Participants will receive a SC injection of olpasiran at dose level 1 or 2.

  • Participants will receive a single dose of moxifloxacin as an oral tablet by mouth.

06

What researchers measure

Primary outcomes

  1. Placebo-corrected Change From Baseline in QT Corrected for Heart Rate (HR) Interval Based on the Fridericia Correction (QTcF) (ΔΔQTcF) After Olpasiran Dosing

    Time frame: Day 3 of Treatment Period 4 (up to approximately 9.5 weeks)

Secondary outcomes

  1. Maximum Observed Concentration (Cmax) of Olpasiran

    Time frame: Up to 10 weeks

  2. Time to Cmax (tmax) of Olpasiran

    Time frame: Up to 10 weeks

  3. Half-life of Olpasiran (t1/2)

    Time frame: Up to 10 weeks

  4. Area Under the Curve From Time 0 to the Last Quantifiable Concentration (AUClast)

    Time frame: Up to 10 weeks

  5. Area Under the Curve From Time 0 to Infinity (AUCinf)

    Time frame: Up to 10 weeks

  6. Change From Baseline in HR

    Time frame: Up to 10 weeks

  7. Change From Baseline in QTcF

    Time frame: Up to 10 weeks

  8. Change From Baseline in PR Interval

    Time frame: Up to 10 weeks

  9. Change From Baseline in QRS Interval

    Time frame: Up to 10 weeks

  10. Placebo-corrected Change From Baseline in HR

    Time frame: Up to 10 weeks

  11. Placebo-corrected Change From Baseline in PR Interval

    Time frame: Up to 10 weeks

  12. Placebo-corrected Change From Baseline in QRS Interval

    Time frame: Up to 10 weeks

  13. Number of Participants with Categorical Outliers Related to the Following ECG parameter: QTcF, HR, PR, and QRS

    Time frame: Up to 10 weeks

  14. Frequency of Treatment-emergent Changes in Electrocardiogram (ECG) Morphology

    Time frame: Up to 10 weeks

  15. ΔΔQTcF After Moxifloxacin Dosing

    Time frame: Up to 10 weeks

  16. Number of Participants With Treatment-emergent Adverse Events

    Time frame: Up to 10 weeks

  17. Number of Participants With Treatment-emergent Serious Adverse Events

    Time frame: Up to 10 weeks

07

Study locations

1 site
  • Fortrea Clinical Research Unit Limited - Leeds
    Leeds, LS11 9EH, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.

Data sharing details ↗ · www.amgen.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2024 to primary completion in Nov 2024, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2024
First posted
May 13, 2024
StartActual
Sep 12, 2024
Primary completionActual
Nov 29, 2024
CompletionActual
Dec 11, 2024
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06411860
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
May 13, 2024
Start date
Sep 12, 2024
Primary completion
Nov 29, 2024
Completion
Dec 11, 2024
Last update
Oct 23, 2026

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olpasiran

Start the discussion